Laca, Ibrahim A.
HRN: 28-11-65 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/04/2026
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
01/04/2026
01/11/2026
IVT
500mg
Q8H
Fistula-in-Ano
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes